Cargando…
Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study
BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1 (PD-1) monoclonal antibody, approved for the tre...
Autores principales: | Guo, Tianxing, Ding, Yun, Chen, Long, Zhu, Lihuan, Lin, Jinlan, Zhang, Jiguang, Huang, Yangyun, Li, Wujin, Lin, Rongjia, Pan, Xiaojie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867846/ https://www.ncbi.nlm.nih.gov/pubmed/33569208 http://dx.doi.org/10.21037/jtd-20-3413 |
Ejemplares similares
-
Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study
por: Lin, Wenbao, et al.
Publicado: (2022) -
CircMED13L_012 promotes lung adenocarcinoma progression by upregulation of MAPK8 mediated by miR-433-3p
por: Chen, Wenshu, et al.
Publicado: (2021) -
TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1
por: Guo, Tianxing, et al.
Publicado: (2022) -
Combination of preoperative fibrinogen and neutrophil to lymphocyte ratio is a predictive prognostic factor in ESCC and AEG systematic review
por: Tianxing, Guo, et al.
Publicado: (2019) -
miR-452-5p suppressed the metastasis of Non-small cell lung cancer through regulating Moesin
por: Zhuang, Jing, et al.
Publicado: (2023)